Literature DB >> 9506352

Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.

F D Groves1, L B Travis, S S Devesa, L A Ries, J F Fraumeni.   

Abstract

BACKGROUND: There are few data describing the epidemiologic aspects of Waldenström's macroglobulinemia (WM), a rare lymphoplasmaproliferative disorder.
METHODS: The authors evaluated the incidence of WM reported in 11 population-based cancer registries in the U.S.
RESULTS: A total of 624 cases were diagnosed between January 1, 1988 (when WM became reportable) and December 31, 1994. Age-adjusted incidence rates for WM (per 1 million person-years at risk) were 3.4 among males and 1.7 among females. The rates increased sharply with age, from 0.1 at age < 45 years to 36.3 at age 75+ years (males) and from 0.1 at age < 45 years to 16.4 at age 75+ years (females). The rates for WM were comparable to those for hairy cell leukemia, but considerably lower than those for multiple myeloma or chronic lymphocytic leukemia. Some geographic variation was evident, with age-adjusted rates among white males ranging from 2.2-7.8 across registries. There was no significant change in rates over the 7-year study period (P > 0.05). The markedly higher rates for WM among whites than blacks stand in contrast to multiple myeloma, which occurs twice as often among blacks.
CONCLUSIONS: This survey provides new data regarding the incidence patterns of WM in the U.S. However, further epidemiologic studies with biomarkers are needed to define the environmental, genetic, immunologic, and viral determinants of this rare but distinctive disorder.

Entities:  

Mesh:

Year:  1998        PMID: 9506352

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

Review 2.  Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Ingemar Turesson; Magnus Björkholm; Ola Landgren
Journal:  Acta Haematol       Date:  2012-02-03       Impact factor: 2.195

3.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

4.  Chronic immune stimulation and subsequent Waldenström macroglobulinemia.

Authors:  Jill Koshiol; Gloria Gridley; Eric A Engels; Mary L McMaster; Ola Landgren
Journal:  Arch Intern Med       Date:  2008-09-22

5.  Monoclonal gammopathies in a Moroccan military hospital.

Authors:  Z Ouzzif; K Doghmi; S Bouhsain; A Dami; S El Machtani; S Tellal; N Messaoudi; M Mikdame; A El Maataoui
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

6.  Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Authors:  Larissa Higgins; Samih H Nasr; Samar M Said; Prashant Kapoor; David Dingli; Rebecca L King; S Vincent Rajkumar; Robert A Kyle; Taxiarchis Kourelis; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Francis K Buadi; Stephen M Ansell; Wilson I Gonsalves; Carrie A Thompson; Fernando C Fervenza; Ladan Zand; Yi L Hwa; Dragan Jevremovic; Min Shi; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-30       Impact factor: 8.237

7.  Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Authors:  Adam J Olszewski; Steven P Treon; Jorge J Castillo
Journal:  Oncologist       Date:  2016-07-29

Review 8.  MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.

Authors:  O Landgren; N Tageja
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

9.  Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Mary L McMaster; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2008-08-13       Impact factor: 22.113

10.  Distal renal tubular acidosis in lymphoplasmacytic lymphoma Waldenström's macroglobulinemia: a case report.

Authors:  Harm Hh Feringa; Afrooz Ardestani; Joseph Gnanaraj
Journal:  Cases J       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.